These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 2182341)

  • 1. Immunohistochemical study of the ras oncogene expression in human bladder endoscopy specimens.
    Agnantis NJ; Constantinidou A; Poulios C; Pintzas A; Kakkanas A; Spandidos DA
    Eur J Surg Oncol; 1990 Apr; 16(2):153-60. PubMed ID: 2182341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation.
    Lee CC; Yamamoto S; Wanibuchi H; Wada S; Sugimura K; Kishimoto T; Fukushima S
    Cancer Res; 1997 Nov; 57(21):4765-76. PubMed ID: 9354438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. H-ras immunohistochemical expression and molecular analysis of urinary bladder lesions in grazing adult cattle exposed to bracken fern.
    Sardon D; de la Fuente I; Calonge E; Perez-Alenza MD; Castaño M; Dunner S; Peña L
    J Comp Pathol; 2005; 132(2-3):195-201. PubMed ID: 15737346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues.
    Ohuchi N; Thor A; Page DL; Hand PH; Halter SA; Schlom J
    Cancer Res; 1986 May; 46(5):2511-9. PubMed ID: 3084069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between the expression of the P21 ras oncogene product and the biological behavior of bladder tumors.
    Miao TJ; Wang Z; Sang N
    Eur Urol; 1991; 20(4):307-10. PubMed ID: 1814747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Oncogene ras P 21 expression and DNA ploidy in human bladder tumor].
    Wang Z
    Zhonghua Zhong Liu Za Zhi; 1991 Jul; 13(4):245-8. PubMed ID: 1806342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocytochemical demonstration of p21ras in normal and transitional cell carcinoma urothelium.
    Dunn TL; Seymour GJ; Gardiner RA; Strutton GM; Lavin MF
    J Pathol; 1988 Sep; 156(1):59-65. PubMed ID: 3057152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression.
    King ED; Matteson J; Jacobs SC; Kyprianou N
    J Urol; 1996 Jan; 155(1):316-20. PubMed ID: 7490878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ras mutations and expression in head and neck squamous cell carcinomas.
    Yarbrough WG; Shores C; Witsell DL; Weissler MC; Fidler ME; Gilmer TM
    Laryngoscope; 1994 Nov; 104(11 Pt 1):1337-47. PubMed ID: 7968162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunohistochemical studies of ras oncogene product p21 in human ovarian tumors].
    Yaginuma Y; Yamashita K
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1409-16. PubMed ID: 2685141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
    Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
    J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ras induced lesions in a heterotopic mouse bladder.
    Wagner HE; Joyce AD; Beatrice K; Summerhayes IC
    Oncogene; 1990 Apr; 5(4):557-63. PubMed ID: 2183157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transgenic rats carrying copies of the human c-Ha-ras proto-oncogene exhibit enhanced susceptibility to N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis.
    Ota T; Asamoto M; Toriyama-Baba H; Yamamoto F; Matsuoka Y; Ochiya T; Sekiya T; Terada M; Akaza H; Tsuda H
    Carcinogenesis; 2000 Jul; 21(7):1391-6. PubMed ID: 10874018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours.
    Le Frère-Belda MA; Cappellen D; Daher A; Gil-Diez-de-Medina S; Besse F; Abbou CC; Thiery JP; Zafrani ES; Chopin DK; Radvanyi F
    Br J Cancer; 2001 Nov; 85(10):1515-21. PubMed ID: 11720438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization.
    Ohuchi N; Hand PH; Merlo G; Fujita J; Mariani-Costantini R; Thor A; Nose M; Callahan R; Schlom J
    Cancer Res; 1987 Mar; 47(5):1413-20. PubMed ID: 2434216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of the ras oncogene protein product in human thyroid neoplasms.
    Papadimitriou K; Yiagnisis M; Tolis G; Spandidos DA
    Anticancer Res; 1988; 8(6):1223-7. PubMed ID: 3064713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder.
    Tong GX; Yee H; Chiriboga L; Hernandez O; Waisman J
    Hum Pathol; 2005 Jul; 36(7):741-6. PubMed ID: 16084942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cytokeratins and transitional epithelium of the bladder. Particular distribution of cytokeratins].
    Fetissof F; Serres G; Haillot O
    Arch Anat Cytol Pathol; 1990; 38(4):159-62. PubMed ID: 1699500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of RAS family genes in urothelial carcinoma.
    Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
    J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTP Toxicology and Carcinogenesis Studies of o-Nitroanisole (CAS No. 91-23-6) in F344 Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 May; 416():1-482. PubMed ID: 12616295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.